利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

58 条记录 (耗时 0.032 秒)

    Stable and soluble antibodies inhibiting TNF alpha
    1.
    发明授权
    Stable and soluble antibodies inhibiting TNF alpha 有权
    稳定和可溶性抗体抑制TNFα

    公开(公告)号：US09422366B2

    公开(公告)日：2016-08-23

    申请号：US14134779

    申请日：2013-12-19

    申请人： ESBATech, an Alcon Biomedical Research Unit LLC

    发明人： Leonardo Borras ,  Tea Gunde ,  David Urech

    IPC分类号： C07K16/24

    CPC分类号： C07K16/241 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/92

    摘要： The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.

    摘要翻译： 本发明涉及特别稳定和可溶的scFv抗体和对TNF特异性的Fab片段，其包含针对TNF的稳定性，溶解性，体外和体内结合以及低免疫原性而优化的特异性轻链和重链序列。 所述抗体被设计用于诊断和/或治疗TNF介导的病症。 还公开了用于表达本发明的重组抗体的核酸，载体和宿主细胞，用于分离它们的方法和所述抗体在医学中的用途。

    Functionalized polypeptides
    3.
    发明授权
    Functionalized polypeptides 有权
    官能化多肽

    公开(公告)号：US08637022B2

    公开(公告)日：2014-01-28

    申请号：US13000499

    申请日：2009-06-30

    申请人： David Urech

    发明人： David Urech

    IPC分类号： A61K38/00

    CPC分类号： C12N15/1062 ,  A61K47/48215 ,  A61K47/48338 ,  A61K47/60 ,  A61K47/65 ,  C07K16/00 ,  C07K16/241 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/622 ,  C07K2319/31 ,  C12N15/1037

    摘要： The invention provides functionalized polypeptides, especially therapeutic polypeptides (e.g., scFv), comprising a linker sequence that can be rapidly and specifically functionalized by the addition of one or functional moieties (e.g., PEG) or binding specificities (e.g., an amino acid sequence with a particular binding specificity). Such functionalized polypeptides are advantageous in that they have improved pharmacokinetic properties (e.g., improved in vivo half-life, tissue penetration and tissue residency time) over non-functionalized polypeptides. Methods for the rapid and reproducible generation of functionalized polypeptides are also provided.

    摘要翻译： 本发明提供功能化多肽，特别是治疗性多肽（例如scFv），其包含可以通过加入一个或多个功能部分（例如PEG）或结合特异性（例如，具有 特异性结合特异性）。 这样的功能化多肽的优点在于它们具有比非功能化多肽更好的药代动力学性质（例如，改善的体内半衰期，组织穿透和组织停留时间）。 还提供了快速和可重复产生功能化多肽的方法。

    Solubility optimization of immunobinders
    8.
    发明授权
    Solubility optimization of immunobinders 有权

    公开(公告)号：US10221237B2

    公开(公告)日：2019-03-05

    申请号：US15378649

    申请日：2016-12-14

    申请人： ESBATech, an Alcon Biomedical Research Unit LLC

    发明人： Leonardo Borras ,  David Urech

    IPC分类号： C07K16/00 ,  C07K16/24 ,  C07K16/22

    摘要： The invention provides methods of using sequence based analysis and rational strategies to improve the solubility of immunobinders, and in particular of single chain antibodies (scFvs). The invention provides methods of engineering immunobinders, and in particular scFvs, by performing one or more substitutions with hydrophilic residues identified by analysis of a database of selected, stable scFv sequences. The invention also provides immunobinders with optimized solubility prepared according to the engineering methods of the invention.